Pregled bibliografske jedinice broj: 1018654
Autoimmune Progesterone Dermatitis Diagnosed by Lymphocyte Transformation Test and Progesterone Provocation Test
Autoimmune Progesterone Dermatitis Diagnosed by Lymphocyte Transformation Test and Progesterone Provocation Test // Acta dermatovenerologica Croatica, 26 (2018), 3; 276-277 (međunarodna recenzija, pismo, stručni)
CROSBI ID: 1018654 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Autoimmune Progesterone Dermatitis Diagnosed by
Lymphocyte Transformation Test and Progesterone
Provocation Test
Autori
Ljubojević Hadžavdić, Suzana ; Marinović Kulišić, Sandra ; Ljubojević Grgec, Dragana ; Poljanac, Ana ; Ilić, Brankica
Izvornik
Acta dermatovenerologica Croatica (1330-027X) 26
(2018), 3;
276-277
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, stručni
Ključne riječi
autoimmune progesterone dermatitis ; diagnosis ; lymphocyte transformation test ; progesterone provocation test ; treatmentst
(autoimmune progesterone dermatitis ; diagnosis ; lymphocyte transformation test ; progesterone provocation test ; treatment)
Sažetak
Autoimmune progesterone dermatitis (APD) is rare autoimmune response to endogenous progesterone or to earlier exposure to exogenous progesterone. Skin lesions typically occur due to increases in progesterone during the luteal phase of the menstrual cycle. A-31-year-old mother of two children presented to our Department with a 5-year history of pruritic and painful erythematosus macules, papules, and patches on her neck, pectoral region, and face, which appeared 2-3 days before the onset of menses and gradually resolved 7-10 days later. We performed multiple laboratory tests that were unremarkable. Histopathological examination of a biopsy taken from a lesion on the neck showed epidermal hyperplasia and nonspecific mild dermal inflammation. Progesterone testing has not been standardized. Most of the sex hormones are not suitable for testing since they contain an oily component that can produce an irritant test reaction. Gestodene, which was used for the oral provocation test in our patient, is a potent progesterone. The LTT shows reactions to circulating lymphocytes and reflects immune reactions within the body. The goal of treatment is suppression of ovulation. Currently, the first- line choice of therapy is a combination oral contraceptive. We believe that OCP have a limited effect because all of them contain a progesterone component. If this treatment is ineffective, patients have been treated with danazol, gonadotropin releasing hormone analogs, conjugated estrogens, tamoxifen, oophorectomy (8), and progestogen desensitization with varying success.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE